Moreover, frequent failure of BCR-ABL kinase inhibitors to eradicate completely CML LSCs suggests the involvement of BCR-ABL kinase-independent intrinsic pathways in LSC maintenance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.